cannabinoid analogs. Further investigations on endocannabinoid system as potential

anticancer regimen is the need of the hour which may transform the area of antican-

cer therapeutic drug development.

References

Aldrich M (1997) History of therapeutic cannabis. In: Mathre ML (ed) Cannabis in medical

practice. McFarland, Jefferson, pp 35–55

An X, Sarmiento C, Tan T, Zhu H (2017) Regulation of multidrug resistance by microRNAs in anti-

cancer therapy. Acta Pharm Sin B 7(1):38–51

Andradas C, Caffarel MM, Perez-Gomez E, Salazar M, Lorente M, Velasco G (2011) The orphan G

protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene 30:

245–252

Arnold JC, Hone P, Holland ML, Allen JD (2012) CB2 and TRPV1 receptors mediate cannabinoid

actions on MDR1 expression in multidrug resistant cells. Pharmacol Rep 64:751–757

Balenga NA, Aflaki E, Kargl J, Platzer W, Schroder R, Blattermann S (2011) GPR55 regulates

cannabinoid 2 receptor-mediated responses in human neutrophils. Cell Res 21:1452–1469

Benito C, Núñez E, Tolon RM (2003) Cannabinoid CB2 receptors and fatty acid amide hydrolase is

selectively overexpressed in neuritic plaque-associated glia in Alzheimer’s disease brains. J

Neurosci 23:11136–11141

Bettiga A, Aureli M, Colciago G, Murdica V, Moschini M, Lucianò R et al (2017) Bladder cancer

cell growth and motility implicate cannabinoid 2 receptor-mediated modifications of

sphingolipids metabolism. Sci Rep 7:42157

Bifulco M, Pisanti S (2015) Medicinal use of cannabis in Europe: the fact that more countries

legalize the medicinal use of cannabis should not become an argument for unfettered and

uncontrolled use. EMBO Rep 16:130–132

Blázquez C, Chiarlone A, Sagredo O, Aguado T, Pazos MR, Resel E (2011) Loss of striatal type

1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain 134:119–136

Bowker J (1997) The Oxford dictionary of world religions. Oxford University Press, Oxford, p 142

Braun A, Engel T, Aguilar-Pimentel JA, ZimmerA JT, Behrendt H (2011) Beneficial effects of

cannabinoids (CB) in a murine model of allergen-induced airway inflammation: role of

CB1/CB2 receptors. Immunobiology 216(4):466–476

Brooks JW, Pryce G, Bisogno T et al (2002) Arvanil-induced inhibition of spasticity and

persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor

and cannabinoid CB (1)/CB (2) receptors. Eur J Pharmacol 439(1–3):83–92

Cacciola G, Chianese R, Chioccarelli T, Ciaramella V, Fasano S, Pierantoni R et al (2010)

Cannabinoids and reproduction: a lasting and intriguing history. Pharmaceuticals 3:3275–3323

Cannabinoids GM (2003) Potential anticancer agents. Nat Rev Cancer 3:745–755

Carracedo A, Gironella M, Lorente M, Garcia S, Guzmán M, Velasco G, Iovanna JL (2006)

Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress–

related genes. Cancer Res 66(13):6748–6755

Chen WJ, Wang H, Tang Y, Liu CL, Li HL, Li WT (2010) Multidrug resistance in breast cancer

cells during epithelial-mesenchymal transition is modulated by breast cancer resistant protein.

Chin J Cancer 29:151–157

ClinicalTrials.gov (n.d.-a) A phase 1 study of dexanabinol in patients with advanced solid tumours.

https://ClinicalTrials.gov/show/NCT01489826

ClinicalTrials.gov (n.d.-b) A study of dexanabinol in combination with chemotherapy in patients

with advanced tumours. https://ClinicalTrials.gov/show/NCT02423239

ClinicalTrials.gov (n.d.-c) A study: pure CBD as single-agent for solid tumor. https://ClinicalTrials.

gov/show/NCT02255292

12

Emerging Role of Cannabinoid System Modulators in Treatment of Cancer

197